Table 11.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1995 to 2004

Recipients with Heart Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 2,363 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057 2,016
Tx with Antirejection Treatments 955 854 871 979 916 900 850 800 657 522
Antibodies Any in Category 20.8% 18.1% 19.3% 21.2% 17.7% 16.3% 15.5% 17.5% 18.4% 14.9%
ALG 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 8.1% 5.4% 7.9% 7.3% 6.3% 4.6% 3.9% 4.0% 4.6% 2.7%
OKT3 14.5% 13.9% 13.1% 14.9% 7.4% 5.1% 5.8% 6.9% 4.1% 3.1%
Thymoglobulin 0.0% 0.0% 0.1% 0.2% 2.0% 3.8% 4.9% 6.4% 7.5% 8.8%
Zenapax 0.0% 0.0% 0.1% 0.8% 2.5% 3.0% 2.5% 1.5% 2.0% 0.8%
Simulect 0.0% 0.0% 0.0% 0.1% 0.9% 2.0% 0.4% 0.4% 1.4% 0.8%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2%
Corticosteroids Any in Category 92.6% 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.1% 92.5% 92.3%
Steroids 92.6% 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.1% 92.5% 92.3%
Antimetabolites Any in Category 6.6% 5.4% 7.6% 6.5% 4.6% 4.4% 2.0% 3.0% 3.5% 1.7%
Cytoxan 1.8% 1.8% 3.6% 2.5% 2.1% 1.7% 0.5% 0.9% 1.7% 1.3%
Methotrexate 4.9% 3.6% 4.1% 4.3% 2.6% 2.8% 1.5% 2.1% 1.8% 0.4%


Source: OPTN/SRTR Data as of May 1, 2006.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.